DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia

Information source: University of Colorado, Denver
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Friedreich Ataxia

Intervention: bupropion & Citalopram (Drug); Bupropion & Placebo (Drug); Placebo & Citalopram (Drug); Placebo & Placebo (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: University of Colorado, Denver

Official(s) and/or principal investigator(s):
Drew Kern, MD, Principal Investigator, Affiliation: University of Colorado, Denver


The purpose of this study is to document the clinical effects of bupropion and citalopram in a single subject with Friedreich Ataxia.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care

Primary outcome:

International Cooperative Ataxia Rating Scale (ICARS)

Friedreich Ataxia Rating Scale (FARS)

Secondary outcome: Comparison of FARS and ICARS


Minimum age: N/A. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: N/A -

Exclusion Criteria: N/A


Locations and Contacts

Additional Information

Starting date: October 2012
Last updated: October 4, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017